Interferon beta 1b (IFN-β1b)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)1.71 [0.37, 7.96]0%2 studies5,00121not evaluable NA
Major congenital malformations1.88 [0.33, 10.69]0%2 studies4,99821not evaluable NA

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)1.32 [0.31, 5.56]61%3 studies20668not evaluable NA

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preeclampsia--0 study
Gestational diabete1.32 [0.05, 34.93]-1 study110not evaluable NA

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Jaundice1.21 [0.14, 10.79]-1 study910not evaluable NA
Neonatal medical care10.44 [0.60, 181.46]-1 study210not evaluable NA

Long term consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Children infections2.00 [0.21, 19.05]-1 study610not evaluable NA

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Intrauterine deaths (as a whole)1.70 [0.43, 6.67]57%2 studies6470not evaluable NA
Elective termination of pregnancy2.27 [0.76, 6.76]-1 study3152not evaluable NA

Hide endpoints reported in only one study ...